Effect of hypoxia on Ad5 infection, transgene expression and replication
- 3 February 2005
- journal article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 12 (11), 902-910
- https://doi.org/10.1038/sj.gt.3302448
Abstract
Oxygen deprivation (hypoxia) is a common feature of various human maladies, including cardiovascular diseases and cancer; however, the effect of hypoxia on Ad-based gene therapies has not been described. In this study, we evaluated how hypoxia (1% pO2) affects different aspects of Ad-based therapies, including attachment and uptake, transgene expression, and replication, in a series of cancer cell lines and primary normal cells. We found that hypoxia had no significant effect on the expression or function of the Ad5 attachment (Coxsackievirus and Adenovirus Receptor) and internalization (v integrins) proteins, nor on the human cytomegalovirus-driven expression of an exogenous gene carried by a replication-incompetent Ad. Viral replication, however, was compromised by hypoxic conditions. Our studies revealed hypoxia-induced reductions in E1A levels that were mediated at the post-transcriptional level. E1A drives cells into the viral replication optimal S phase of the cell cycle; consequently, the combination of reduced E1A protein and hypoxia-induced G1 arrest of cells may be responsible for the lack of efficient viral replication under hypoxic conditions. Consequently, while traditional replication-incompetent Ad-based vectors appear to be viable delivery systems for hypoxia-associated disease indications, our studies suggest that Oncolytic Ads may need additional factors to efficiently treat hypoxic regions of human tumors.Keywords
This publication has 48 references indexed in Scilit:
- Genome-wide analysis of the endothelial transcriptome under short-term chronic hypoxiaPhysiological Genomics, 2004
- Ad-mTERT-Δ19, a Conditional Replication-Competent Adenovirus Driven by the Human Telomerase Promoter, Selectively Replicates in and Elicits Cytopathic Effect in a Cancer Cell-Specific MannerHuman Gene Therapy, 2003
- Replicative Oncolytic Adenoviruses in Multimodal Cancer RegimensHuman Gene Therapy, 2003
- Hypoxia-mediated tumour targetingGene Therapy, 2003
- Target validation in hypoxia-induced vascular remodeling using transcriptome/metabolome analysisThe Pharmacogenomics Journal, 2003
- A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerCancer Gene Therapy, 2002
- Oncolytic biotherapy: a novel therapeutic platformThe Lancet Oncology, 2002
- Hypoxia as a target for combined modality treatmentsEuropean Journal Of Cancer, 2002
- Integrin αvβ1 Is an Adenovirus CoreceptorJournal of Virology, 2001
- Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachmentCell, 1993